There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pfizer (PFE – Research Report) and Actinium Pharmaceuticals (ATNM – Research Report) with bullish sentiments.
Pfizer (PFE)
In a report released today, Trung Huynh from Credit Suisse maintained a Buy rating on Pfizer, with a price target of $55.00. The company’s shares closed last Monday at $52.16.
According to TipRanks.com, Huynh is a 5-star analyst with an average return of
Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $53.08, a 1.8% upside from current levels. In a report released today, Goldman Sachs also upgraded the stock to Buy with a $60.00 price target.
See the top stocks recommended by analysts >>
Actinium Pharmaceuticals (ATNM)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals yesterday and set a price target of $35.00. The company’s shares closed last Monday at $10.59.
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $32.50 average price target, implying a 206.9% upside from current levels. In a report issued on December 9, B.Riley Financial also reiterated a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PFE:
- Pfizer to Expand Its mRNA Vaccine Arsenal
- Canada approves Pfizer, BioNTech booster vaccine for children 5 to 12
- Pfizer raises quarterly cash dividend to 41c from 40c per share
- Pfizer, BioNTech get FDA FTD for mRNA-based combination vaccine candidate
- Pfizer, BioNTech announce EUA for bivalent COVID vaccine for children under 5
